Related Experiment Video
Updated: Jul 27, 2026
07:51
The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Published on: June 1, 2019
Sentinel lymph node--why study it: implications of the B-32 study
1Department of Surgery, University of Vermont College of Medicine, Burlington, VT 05405-0068, USA.
Seminars in Surgical Oncology
|August 28, 2001
Summary
Sentinel lymph node (SLN) biopsy offers accurate staging for breast cancer patients. This clinical trial compares SLN biopsy alone versus with axillary dissection to evaluate safety and effectiveness.
Area of Science:
- Oncology
- Surgical Oncology
- Clinical Trials
Background:
- Axillary lymph node dissection is the standard for breast cancer staging and regional control but causes significant morbidity.
- Sentinel lymph node (SLN) biopsy provides accurate staging but its impact on long-term outcomes is unknown.
Purpose of the Study:
- To compare the safety and efficacy of SLN biopsy alone versus SLN biopsy with completion axillary node dissection.
- To evaluate the impact of SLN biopsy on regional disease control and patient survival in breast cancer management.
Main Methods:
- Phase III prospective, randomized clinical trial (B-32 trial) sponsored by the National Cancer Institute (NCI).
- Comparison of treatment arms: SLN biopsy alone vs. SLN biopsy plus completion axillary node dissection.
- Patient population: Clinically node-negative breast cancer patients.
Main Results:
- The trial aims to provide evidence regarding the safety of SLN biopsy procedures.
- Results will determine if SLN biopsy alone is non-inferior to axillary dissection for regional disease control and survival.
Conclusions:
- SLN biopsy is a less invasive staging procedure for breast cancer.
- The B-32 trial will establish the role of SLN biopsy in breast cancer management and patient outcomes.
